Becker's Healthcare November 20, 2025
Obesity treatment is entering a transformative era — and few therapies have garnered more attention or raised more questions than GLP-1 receptor agonists. In a featured session at Becker’s Fall 2025 Payer Issues Roundtable, Lia Gass Rodriguez, MD, chief medical officer at CVS Healthspire Payor Solutions, explored the complex terrain of GLP-1 drugs, outlining a strategy grounded in clinical science, care integration and fiscal responsibility.
Here are four key takeaways from her session:
1. Obesity is a chronic, multifactorial disease, not a failure of willpower.
Dr. Rodriguez began by reframing obesity not as a lifestyle issue, but as a chronic, complex condition driven by behavioral, environmental and genetic factors. While healthy habits remain important, the stigma surrounding obesity often obscures...
Today's Sponsors
Today's Sponsor